ReviewFrontiers in pharmacology2022
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Qualitative and Quantitative Characterization of Isodon rubescens and Its Pharmaceutical Preparations Using NMR and UHPLC-QTOF-MS.Magnetic resonance in chemistry : MRC · 2026Article
- Targeting Skin Cancer with Natural Bioactive Compounds: From Molecular Mechanisms to Application Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Anti-inflammatory role of metal and metal oxide nanoparticles: a review of toxicity, green synthesis, and immunomodulatory mechanisms.Inflammopharmacology · 2026Review
- Plant Terpenoids in Cardioprotection: An Overview of Their Therapeutic Potential.Current issues in molecular biology · 2026Review
- Genomic insights into adaptive divergence and genetic vulnerability to climate change of the medicinal plant Isodon rubescens (Hemsl.) H. Hara in central China.BMC plant biology · 2026Article
- Network pharmacology-guided identification of Rabdosia rubescent as a suppressor of laryngeal cancer via MMP9-mediated extracellular matrix remodeling: integratedFrontiers in pharmacology · 2026Article
- Longikaurin A - Mediated Regulation of ROS/JNK Signaling Counteracts Epithelial-Mesenchymal Transition in Glioblastoma.Neuromolecular medicine · 2025Article
- Characterization and differential expression of DNA methyltransferase and demethylase genes in response to abiotic stress in Isodon rubescens.BMC plant biology · 2025Article
- Integrated miRNAome, transcriptome, and degradome analyses reveal the role of miRNA-mRNA modules in the biosynthesis of oridonin inFrontiers in plant science · 2025Article
- Article
- Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance.Chinese medicine · 2024Review
- Oridonin fromFood science & nutrition · 2024Review
- Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.Frontiers in pharmacology · 2024Review
- Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis.Journal of Cancer · 2024Article
- From Omics Analysis toward Physiological Mechanism Research in Plants.Life (Basel, Switzerland) · 2023Article
- Ethnobotanical, Phytochemical, and Pharmacological Properties of the Subfamily Nepetoideae (Lamiaceae) in Inflammatory Diseases.Plants (Basel, Switzerland) · 2023Review
- Guidongnins I-J: Two New 6,7-International journal of molecular sciences · 2023Article
- Cirsiliol and Quercetin Inhibit ATP Synthesis and Decrease the Energy Balance in Methicillin-ResistantMolecules (Basel, Switzerland) · 2023Article
- Ternifolipyrons A-J: new cytotoxic α-pyrones fromRSC advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.